AG
KPTI icon

Advisor Group’s Karyopharm Therapeutics KPTI Stock Holding History

Advisor Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$24K Hold
85
– – ﹤0.01% 3863
2019
Q3 		$13K Buy
85
+40
+89% +$5.42K ﹤0.01% 4207
2019
Q2 		$4K Sell
45
-67
-60% -$5.38K ﹤0.01% 4765
2019
Q1 		$10K Buy
112
+74
+195% +$8.2K ﹤0.01% 4375
2018
Q4 		$6K Buy
38
+13
+52% +$2.19K ﹤0.01% 4437
2018
Q3 		$7K Hold
25
– – ﹤0.01% 4452
2018
Q2 		$7K Buy
+25
New +$6.18K ﹤0.01% 4249

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Advisor Group's KPTI Position: Q4 2019 in Review

Advisor Group held its Karyopharm Therapeutics (KPTI) position steady in Q4 2019 at 85 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3863.

Advisor Group first reported a position in KPTI in Q2 2018 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold KPTI as of Q4 2019.

  • Advisor Group held 85 shares of Karyopharm Therapeutics worth $24K as of Q4 2019.
  • Advisor Group left its Karyopharm Therapeutics share count unchanged in Q4 2019.
  • Karyopharm Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3863 holding.
  • Advisor Group first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.